DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jaap Arriens - 1 Eli Lilly - 1 Adam Steensberg - 1 Steensberg - 1 Petrelintide - 1
Top related locs:
U.S Hillerod Denmark Danish
Top related orgs:
Zealand Pharma - 2 Novo Nordisk - 2 CNBC - 1 pharma - 1 Nordisk - 1 Union - 1 Getty - 1 Denmark's Zealand Pharma - 1

Search resuls for: "Petrelintide"


2 mentions found


☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
  + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com   time to read: +4 min
Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."
Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S
☆ Weight loss drug contender Zealand Pharma jumps 23% on trial results
  + stars: | 2024-06-21 | by ( Jenni Reid | ) www.cnbc.com   time to read: +1 min
Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. LONDON — Shares of Denmark's Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. Petrelintide was "judged to be safe and well tolerated at all dose levels" and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release. GLP-1RA-based treatments include Ozempic, the diabetes drug produced by fellow Danish pharmaceutical firm Novo Nordisk , which has exploded in popularity globally for its weight-loss effects. Soaring demand for Ozempic and obesity drug Wegovy have propelled Novo Nordisk to become Europe's most valuable company.
Persons: Petrelintide Organizations: Novo Nordisk, Denmark's Zealand Pharma, Zealand Pharma Locations: Hillerod, Denmark, Danish
0 next >>
Total: 2